Partner Karen Cassidy was quoted in “New written description rule set out by Federal Circuit in precedential Contrave Judgement” an article published by IAM-Media.
Excerpt: The holding of the Nalpropion case was fairly limited—the Federal Circuit specifically reiterated that generally, “equivalent disclosures” would not be sufficient for written description. However, in certain instances, Nalpropion may still provide an additional defense for patentees fending off written description challenges.
Read the full article here >> (Subscription Required)
